Table 3.
IC50 values (in μM) of 5-FU, Oxa, and Iri, obtained in monotherapy (MT) and in combined therapy with AA (CT), with f = 0.5 or f = 0.75, obtained after treatment of C2BBe1, LS1034, and WiDr cells for 24, 48, 72, and 96 h.
| 5-FU |
Oxa |
Iri |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cell line | Time (h) | MT | CT (f = 0.5) | CT (f = 0.75) | MT | CT (f = 0.5) | CT (f = 0.75) | MT | CT (f = 0.5) | CT (f = 0.75) |
| C2BB e1 | 24 | (a) | (a) | (a) | 115.2 | 0.7 | 0.4 | (b) | 8.8 | 3.1 |
| 48 | (b) | 18.1 | 6.9 | 5.2 | 1.0 | 0.3 | 132.6 | 17.0 | 5.0 | |
| 72 | 58.1 | 10.7 | 5.2 | 3.1 | 0.4 | 0.1 | 75.9 | 10.3 | 2.9 | |
| 96 | 20.1 | 3.1 | 1.3 | 2.2 | 0.5 | 0.2 | 11.9 | 6.1 | 2.2 | |
| LS1034 | 24 | (a) | (a) | (a) | 31.9 | 3.9(c) | 0.5 | 83.4 | 3.2 | (b) |
| 48 | 238.0 | 6.3 | 2.6 | 5.9 | 0.5 | 0.4 | 47.5 | 1.4(c) | 0.5 | |
| 72 | 15.4 | 6.3 | 1.4 | 1.9 | 1.2 | 0.3 | 8.1 | 4.3 | 1.1(c) | |
| 96 | 6.7 | 1.5(c) | 0.8 | 2.0 | 0.6 | 0.3 | 4.8 | 1.5(c) | 0.5 | |
| WiDr | 24 | (a) | (a) | (a) | (b) | 7.7 | 4.9 | (b) | (b) | 1.4 |
| 48 | 442.4 | 3.4 | 1.4 | 21.0 | 2.6 | 1.5 | 38.7 | 1.6 | 0.8 | |
| 72 | 10.5 | 1.6 | 1.1 | 10.9 | 0.8 | 0.2 | 13.9 | 1.8 | (b) | |
| 96 | 2.8 | 0.9 | 0.5 | 8.2 | 0.8 | 0.4 | 1.8 | 0.9(c) | 0.4 | |
(a) Represents non-evaluated conditions, (b) represents conditions for which it was not possible to determine the IC50 value, and (c) represents conditions for which the obtained r2 was lower than 0.9.